Unlike our competitors, who charge for a fixed number of variants regardless of quality, we continue applying our proven experience until we reach the optimum humanised candidate. With our approach you only pay for success –  we will deliver the best candidate and you  don’t have to risk wasting time or money.

Technology

We utilise specialised antibody humanisation processes involving a combination of homology modelling, in silico design, CDR grafting and framework optimisation.

Adding value

We also offer extensive biophysical characterisation of lead candidates and affinity maturation capabilities to ensure optimal performance.

Typical timeframe

Once a project has been scheduled, it will normally take 12-15 weeks to design the variants, build the constructs and screen for the optimum candidate antibody.

Unrivalled experience

Oncology, Merck – Keytruda®

Ulcerative colitis, Takeda – Entyvio®

Rheumatoid arthritis, Roche – Actemra®

Multiple sclerosis Biogen, IDEC – Tysabri®

Our antibody engineering service has successfully humanised over 60 antibodies including four drugs on the market and four in clinical trials.

Our engineering process

Sequencing

The mouse heavy and light chain variable antibody genes are extracted from the client’s hybridoma cell line using our proprietary amplification primers in a polymerase chain reaction (PCR) and then
sequenced.

In silico modelling/Humanisation design

Humanisation design starts with selecting human antibody gene fragment regions from our extensive, proprietary database. Rodent CDRs are then grafted into the human frameworks.

Synthesis/Chimerisation

We synthesise all of the humanised antibody variants identified in the design process. We also make a chimeric antibody, by combining the mouse antibody variable genes with human antibody constant genes. This acts as a positive control for the humanised variants during screening.

Screening/Selection of candidates

The heavy and light chain humanised antibody candidates are combined in all possible combinations, and screened against the chimeric antibody for retention of antigen binding affinity, specificity,
expression and biophysical profile. The strongest candidate(s) is then selected.

Get in touch

To discuss further, contact John Kelly + 44 (0) 143 854 4965.